Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group

Category	Detail
Condition	Hematopoietic system disorders and other life-threatening diseases treatable by HSCT
Key Mechanisms	Hematopoietic stem cell transplantation (HSCT) using allogeneic or autologous stem cells from various donor types
Target Population	Patients with hematologic malignancies, aplastic anemia, myelodysplastic syndrome, thalassemia, lymphoma, and other indications
Care Setting	Specialized transplant centers across China

In 2019, China performed over 12,000 HSCTs for the first time, with 78% allogeneic and 22% autologous transplants.
Haploidentical donor (HID) HSCT accounted for 60% of allogeneic transplants, surpassing matched sibling and unrelated donor transplants.
Main indications for allogeneic HSCT were acute leukemia (AML and ALL), aplastic anemia, and myelodysplastic syndrome; autologous HSCT was mainly for multiple myeloma and non-Hodgkin’s lymphoma.

Identify hematologic and other eligible diseases requiring HSCT based on clinical and laboratory criteria.

Select appropriate donor type: HID, matched sibling donor (MSD), unrelated donor (URD), or cord blood (CB) based on availability and patient factors.
Use conditioning regimens and graft-versus-host disease (GVHD) prophylaxis protocols as per center standards.
Consider patient age and disease indication in transplant planning.

Regular follow-up for transplant outcomes, graft function, and GVHD surveillance.
Data collection and reporting to national registry every 6 months.

Potential complications include graft-versus-host disease, transplant-related mortality, and disease relapse.

Patients ranging from pediatric (≤18 years) to elderly (>60 years) with hematologic diseases undergoing HSCT in China.

Majority of pediatric patients receive allogeneic HSCT; elderly patients have lower rates of allogeneic HSCT. HID HSCT is increasingly utilized.

Centralized data collection through national registry to monitor HSCT trends and outcomes.
Utilization of HID HSCT to expand donor availability.
Tailoring transplant approach based on patient age, disease type, and donor availability.
Maintaining multidisciplinary teams in specialized centers to optimize transplant volume and expertise.

Clinical Scorecard: Hematopoietic Stem Cell Transplantation Trends in China for 2019: Insights from the Chinese Blood and Marrow Transplantation Registry Group